OD2-4 Efficient and noninvasive T cell therapy platform using autologous peripheral blood PD-1+CD8+ T cells instead of tumor-infiltrating lymphocytes in solid tumors: Ex vivo efficacy

MLA

Y.W. Moon, et al. “OD2-4 Efficient and Noninvasive T Cell Therapy Platform Using Autologous Peripheral Blood PD-1+CD8+ T Cells Instead of Tumor-Infiltrating Lymphocytes in Solid Tumors: Ex Vivo Efficacy.” ESMO Open, vol. 7, Dec. 2022, p. 100668. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........aa5feb06ca1dc7d521c6681c487f179b&authtype=sso&custid=ns315887.

APA

Y.W. Moon, S. Lee, J. Lee, S.K. Kim, I. Kim, W.D. Joo, S.G. Jung, M.C. Choi, H. Park, C. Lee, Y-G. Chung, K.S. Kim, Y.H. Park, & R.H. Seong. (2022). OD2-4 Efficient and noninvasive T cell therapy platform using autologous peripheral blood PD-1+CD8+ T cells instead of tumor-infiltrating lymphocytes in solid tumors: Ex vivo efficacy. ESMO Open, 7, 100668.

Chicago

Y.W. Moon, S. Lee, J. Lee, S.K. Kim, I. Kim, W.D. Joo, S.G. Jung, et al. 2022. “OD2-4 Efficient and Noninvasive T Cell Therapy Platform Using Autologous Peripheral Blood PD-1+CD8+ T Cells Instead of Tumor-Infiltrating Lymphocytes in Solid Tumors: Ex Vivo Efficacy.” ESMO Open 7 (December): 100668. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........aa5feb06ca1dc7d521c6681c487f179b&authtype=sso&custid=ns315887.